ArticleTranslational cancer research2025
Constructing an immune-related prognostic model and exploring the function of HMGB3, TNFSF4, and CORO2A in breast cancer.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrative analysis of HMGB3 in esophageal carcinoma: expression profile, prognostic significance, and immune microenvironment associations.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer (BC) is clinically defined as a cold tumor due to its low immunogenicity, which is usually insensitive to immunosuppressive agents. Herein, we investigated the predictive potential of novel immune-related genes (IRGs) in BC, with the objective of more effectively guiding the immunotherapy for patients with BC. Methods: The least absolute shrinkage and selection operator (LASSO) regression analysis was used to conduct the BC prognostic model based on IRGs, and univariate/multivariate Cox proportional hazards models were employed to establish the BC predictive nomograms. Then, we investigated the expression patterns of these IRGs utilizing The Cancer Genome Atlas (TCGA) database. Moreover, we also performed correlation analyses between IRGs and multiple immune features, including infiltration of immune cells, immune checkpoint members, and immune therapy response. Results: In our study, six IRGs were finally identified to construct the BC prognostic model, including Conclusions: This prognostic model reliably assessed risk for BC patients, providing critical guidance for precision oncology protocols and dynamic surveillance of disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.